Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 293.00 GBp
Change Today -4.50 / -1.51%
Volume 16.8K
SLN On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 11:35 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

silence therapeutics plc (SLN) Snapshot

Open
295.00 GBp
Previous Close
297.50 GBp
Day High
296.25 GBp
Day Low
293.00 GBp
52 Week High
06/1/15 - 335.00 GBp
52 Week Low
10/16/14 - 168.00 GBp
Market Cap
201.5M
Average Volume 10 Days
10.0K
EPS TTM
-0.22 GBp
Shares Outstanding
68.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SILENCE THERAPEUTICS PLC (SLN)

Related News

No related news articles were found.

silence therapeutics plc (SLN) Related Businessweek News

No Related Businessweek News Found

silence therapeutics plc (SLN) Details

Silence Therapeutics plc, a biotechnology company, discovers, develops, and delivers RNA interference (RNAi) therapeutics for the treatment of serious diseases primarily in North America and the Asia/Pacific. It has AtuRNAi, an RNAi platform, which encompasses the generation of potent chemically stabilized siRNA molecules. The company also has proprietary siRNA delivery technology platforms that comprise AtuPLEX, which delivers siRNA to the endothelial cells of the vascular system; DACC delivery system that delivers siRNA to the vascular endothelial cells of the lung; and DBTC delivery system, which delivers siRNA to hepatocytes and the hepatic vascular system of the liver parenchyma. Its products include Atu027, which is in the Phase IIa clinical trial for the treatment of pancreatic cancer, as well as in the Phase Ib clinical trial for head and neck cancer; Atu111 that is in pre-clinical stage for the treatment of lung diseases; and Atu112, which is in the pre-clinical stage for the treatment of systemic disorders. The company is also developing products for immunotherapy. Silence Therapeutics plc has partnership and collaboration agreements with various pharmaceutical companies, including Pfizer/Quark Pharmaceuticals, Novartis, AstraZeneca, Dainippon Sumitomo Pharma Co., Ltd., InteRNA Technologies B.V., Mirna Therapeutics Inc., and miRagen Therapeutics, Inc. The company was incorporated in 1994 and is based in London, the United Kingdom.

silence therapeutics plc (SLN) Top Compensated Officers

Chief Executive and Director
Total Annual Compensation: 70.0K GBP
Finance Director, Company Secretary and Direc...
Total Annual Compensation: 119.0K GBP
Chief Operating Officer
Total Annual Compensation: 58.0K GBP
Chief Medical Officer and Director
Total Annual Compensation: 53.0K GBP
Compensation as of Fiscal Year 2013.

silence therapeutics plc (SLN) Key Developments

Silence Therapeutics plc Announces Preliminary Analysis of its Phase 2A Trial of Atu027 in Pancreatic Cancer

Silence Therapeutics plc announced preliminary analysis of its Phase 2a trial of Atu027 in pancreatic cancer (Atu027-I-02). The positive results have led the Board to review its strategic use of resources in cancer, including the design and initiation of the proposed head and neck cancer study. The Company believes that the implication of higher and more frequent dosing warrants investigation prior to a full Phase 2 study in pancreatic cancer patients. As a result, the head and neck cancer study, as originally designed, has been deferred to enable the Company to explore this dosing issue further. Once the dosing regimen has been optimised in pancreatic cancer, other metastatic cancers like head and neck can be addressed. At this stage the Company will focus on achieving definitive success in pancreatic cancer, measured in terms of clear endpoints. A further statistical analysis of the pancreatic cancer study, which is expected to confirm the early indications of benefit of Atu027, will be made available in the company's AGM statement, which is due to be released on 1 June 2015.

Silence Therapeutics plc, Annual General Meeting, Jun 01, 2015

Silence Therapeutics plc, Annual General Meeting, Jun 01, 2015., at 10:00 GMT Standard Time. Location: 1 Lyric Square.

Silence Therapeutics plc Presents at BioEquity Europe 2015, May-19-2015 03:20 PM

Silence Therapeutics plc Presents at BioEquity Europe 2015, May-19-2015 03:20 PM. Venue: InterContinental Vienna, Vienna, Austria.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SLN:LN 293.00 GBp -4.50

SLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.75 AUD +0.005
Galena Biopharma Inc $1.68 USD -0.05
Marina Biotech Inc $0.47 USD +0.0299
Regulus Therapeutics Inc $10.20 USD -0.34
View Industry Companies
 

Industry Analysis

SLN

Industry Average

Valuation SLN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10,172.5x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13,617.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SILENCE THERAPEUTICS PLC, please visit www.silence-therapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.